13F Holdings
中文EN

CRON Cronos Group Inc.

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1656472 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY55.8%
TTM net income YoY60.2%
TTM EPS YoY60.0%
Revenue 3-yr CAGR34.2%
Net income 3-yr CAGR—

Margins

Gross margin46.6%
Operating margin3.4%
Net margin28.0%
FCF margin31.7%
EBITDA margin7.4%

Returns

ROE5.4%
ROA4.9%
ROIC (approx.)1.5%
Asset turnover0.17x

Leverage & solvency

Liabilities / assets6.1%
Debt / equity0.00x
Current ratio12.71x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.40x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue7.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$146.59M$117.61M$87.24M$86.75M$64.56M
Gross profit$62.76M$25.20M$11.91M$15.44M-$17.59M
R&D expense$4.45M$4.23M$5.84M$13.13M$21.84M
SG&A expense$42.00M$46.51M$49.48M$67.67M$90.92M
Operating income-$17.39M-$76.53M-$84.80M-$111.43M-$291.97M
Interest expense———$13,000$27,000
Pretax income-$17.12M$36.59M-$73.67M-$121.00M-$128.51M
Income tax-$14.19M-$3.44M-$3.23M$34.17M-$431,000
Net income-$9.45M$41.08M-$73.96M-$168.73M-$396.11M
EBITDA-$3.16M-$67.19M-$76.69M-$98.31M-$276.57M
EPS (basic)-0.020.11-0.19-0.45-1.07
EPS (diluted)-0.020.11-0.19-0.45-1.07
Weighted avg. shares (diluted)383.47M385.56M380.96M376.96M370.39M
Balance sheet
Cash & equivalents$791.79M$858.80M$669.29M$764.64M$886.97M
Short-term investments$40.00M$0$192.24M$113.08M$117.68M
Receivables$34.10M$15.46M$13.98M$23.11M$22.07M
Inventory$46.75M$33.15M$30.50M$37.56M$32.80M
Current assets$944.09M$936.11M$933.31M$960.16M$1.08B
PP&E, net$145.87M$133.19M$59.47M$60.56M$74.07M
Goodwill$66.48M$63.45M$1.06M$1.03M$1.10M
Intangibles$8.89M$11.26M$21.08M$26.70M$18.08M
Total assets$1.20B$1.17B$1.14B$1.21B$1.40B
Current liabilities$48.19M$49.70M$41.40M$68.12M$54.37M
Total liabilities$54.18M$55.33M$44.14M$72.05M$63.46M
Shareholders' equity$1.09B$1.06B$1.10B$1.14B$1.34B
Shares outstanding381.59M382.53M381.30M380.58M374.95M
Cash flow statement
Operating cash flow$25.87M$18.84M-$42.84M-$88.95M-$153.62M
Capital expenditure$25.72M$12.41M$2.50M$3.45M$11.14M
Free cash flow$149,000$6.43M-$45.34M-$92.40M-$164.76M
Investing cash flow-$76.56M$175.15M-$59.50M-$1.84M-$28.90M
Financing cash flow-$19.91M-$1.23M-$1.03M-$2.90M-$13.44M
Depreciation & amortization$14.23M$9.34M$8.11M$13.12M$15.40M
Stock-based compensation$7.05M$8.70M$8.77M$15.12M$10.15M
Share buybacks$9.74M$0$0——

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.